Prof Dr Volker M Lauschke, Associate Professor in Personalized Medicine and Drug Development &
Director of the Micro- and Nanofabrication Facility, Karolinska Institutet
Volker M. Lauschke is Associate Professor and group leader in Personalized Medicine and Drug Development as well as Director of the Micro- and Nanofabrication Facility at Karolinska Institutet, Stockholm, Sweden. His research group uses 3D cell culture systems of primary human cells, microfluidics and integrative bioinformatics approaches to identify novel therapeutic strategies for complex metabolic diseases, such as non-alcoholic fatty liver disease and type 2 diabetes. In addition, the lab develop machine learning tools to improve personalized pharmacological therapy and establish novel methods for the prediction of drug toxicity. V.M.L. is an Oversea Fellow of the Royal Society of Medicine and a member of multiple Editorial Boards. In 2016 he was awarded the Lennart Philipson Award. In addition, he is co-founder and CEO of HepaPredict AB, a biotech company offering in-house evaluations of drug metabolism, pharmacokinetic properties and safety as well as drug target validations based on a novel microphysiological 3D spheroid culture platform.